Drug manufacturer Daiichi-Sankyo is offering 340B covered entities refunds for overcharges on metastatic breast cancer treatment Enhertu during Q1 2020 and on cholesterol medication Welchol for Oral Suspension during Q1 2022 and Q4 2022.
The U.S. Health Resources and Services Administration posted DSI’s notice to covered entities yesterday. The company said it “recalculated 340B ceiling prices and will offer refunds to affected covered entities.”
“DSI has determined the refund amount owed to each affected covered entity,” the notice said. Apexus, the 340B prime vendor, will “issue refund checks in the appropriate amount to affected covered entities,” it said. The notice includes contact information for entities that think “they are due a refund and are not contacted by Apexus by June 21, 2023.”
This is the eighth manufacturer notice to entities this year about refunds for 340B program overcharges.